NCT07529626 Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer
| NCT ID | NCT07529626 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Zhongshan Hospital |
| Condition | Pancreatic Tumor, Benign |
| Study Type | OBSERVATIONAL |
| Enrollment | 320 participants |
| Start Date | 2026-05-11 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 320 participants in total. It began in 2026-05-11 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, observational cohort study (MIND-PANC) to explore the associations of chronic psychological stress with disease progression, treatment outcomes, and prognosis of pancreatic cancer. Researchers will ask participants to fill out simple questionnaires about their mood, worries, and sleep at the start of the study and at regular follow-up visits. The study will also collect a small blood sample (leftover from routine care) to measure stress-related markers. Investigators hypothesize that pancreatic cancer patients who have higher levels of ongoing psychological stress (such as anxiety, depression, or poor sleep) tend to have shorter survival times, a higher chance of recurrence, and a poorer response to treatment, compared to patients with lower stress levels.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years. * Histologically or cytologically confirmed diagnosis of pancreatic cancer, or other pancreatic diseases. * Conscious, with basic reading/writing or communication skills, able to understand and complete the questionnaire assessments (either independently, with assistance from research staff, or with help from a family member). * Voluntarily agree to participate in this study and sign a written informed consent form. Exclusion Criteria: * Presence of severe cognitive impairment (e.g., dementia, disturbance of consciousness) or a definite history of psychiatric disorders, judged by the investigator as unable to comply with the study assessments, and without a family member who can help complete the questionnaire assessments. * Presence of other severe, uncontrolled systemic diseases (e.g., severe heart, lung, or kidney failure), with an estimated life expectancy \< 3 months as judged by the investigator. * Inability to understand Chinese or presence of severe visual/hearing impairment that affects completion of the questionnaire assessments, and without a family member who can help complete the questionnaire assessments.
Frequently Asked Questions
Who can join the NCT07529626 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Tumor, Benign. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07529626 currently recruiting?
Yes, NCT07529626 is actively recruiting participants. Visit ClinicalTrials.gov or contact Shanghai Zhongshan Hospital to inquire about joining.
Where is the NCT07529626 trial being conducted?
This trial is being conducted at Changsha, China, Shanghai, China, Xi’an, China.
Who is sponsoring the NCT07529626 clinical trial?
NCT07529626 is sponsored by Shanghai Zhongshan Hospital. The trial plans to enroll 320 participants.